These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22210435)

  • 1. Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid.
    Schwameis R; Fille M; Manafi M; Zeitlinger M; Sauermann R
    Res Microbiol; 2012 Apr; 163(3):157-60. PubMed ID: 22210435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The post-antibiotic effects of linezolid against Gram-positive pathogens.
    Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
    Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro.
    Sauermann R; Schwameis R; Fille M; Ligios ML; Zeitlinger M
    J Antimicrob Chemother; 2009 Oct; 64(4):821-3. PubMed ID: 19622535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of staphylococci to linezolid and other antimicrobial agents.
    Poiată A; Tuchiluş C; Bădicuţ I; Grigore L; Buiuc D
    Roum Arch Microbiol Immunol; 2002; 61(4):293-9. PubMed ID: 15055263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus].
    Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S
    Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro.
    Sauermann R; Schwameis R; Fille M; Ligios ML; Zeitlinger M
    J Antimicrob Chemother; 2008 Nov; 62(5):1057-60. PubMed ID: 18658192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syntheses and antibacterial activity of a series of 3-(pyridine-3-yl)-2-oxazolidinone.
    Cui Y; Dang Y; Yang Y; Zhang S; Ji R
    Eur J Med Chem; 2005 Feb; 40(2):209-14. PubMed ID: 15694656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
    Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G
    J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
    Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
    J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ; Chmelařová E
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.
    Wiederhold NP; Coyle EA; Raad II; Prince RA; Lewis RE
    J Antimicrob Chemother; 2005 May; 55(5):792-5. PubMed ID: 15814598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
    Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus.
    Baos E; Candel FJ; Merino P; Pena I; Picazo JJ
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):325-9. PubMed ID: 23726146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activity of LCB01-0062, a novel oxazolidinone.
    Jung SJ; Yun IN; Park HS; Lee HH; Jeong JW; Kim YZ; Cho YL; Kwak JH
    Int J Antimicrob Agents; 2012 Dec; 40(6):539-43. PubMed ID: 23058227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.
    Pillai SK; Sakoulas G; Wennersten C; Eliopoulos GM; Moellering RC; Ferraro MJ; Gold HS
    J Infect Dis; 2002 Dec; 186(11):1603-7. PubMed ID: 12447736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1996 Mar; 40(3):799-801. PubMed ID: 8851617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.